N
86.74
-4.95 (-5.39%)
| Penutupan Terdahulu | 91.68 |
| Buka | 91.87 |
| Jumlah Dagangan | 1,524,641 |
| Purata Dagangan (3B) | 1,271,096 |
| Modal Pasaran | 2,880,665,088 |
| Harga / Jualan (P/S) | 22.06 |
| Harga / Buku (P/B) | 23.06 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 7 May 2026 |
| Margin Keuntungan | -152.49% |
| Margin Operasi (TTM) | -424.15% |
| EPS Cair (TTM) | -9.45 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -51.70% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 1,358.71% |
| Nisbah Semasa (MRQ) | 3.24 |
| Aliran Tunai Operasi (OCF TTM) | -176.87 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -47.84 M |
| Pulangan Atas Aset (ROA TTM) | -26.80% |
| Pulangan Atas Ekuiti (ROE TTM) | -189.46% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Nektar Therapeutics | Menaik | Menaik |
AISkor Stockmoo
0.6
| Konsensus Penganalisis | 3.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -4.5 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 4.0 |
| Purata | 0.63 |
|
Nektar Therapeutics is a clinical-stage, research-based drug discovery biopharmaceutical company focused on discovering and developing medicines in the field of immunotherapy. The company is focused on discovering and developing medicines in the field of immunotherapy. Its pipeline products are REZPEG (NKTR-358), REZPEG (NKTR-358), REZPEG (NKTR-358), NKTR-422, NKTR-0165, NKTR-255, and Others. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 1.29% |
| % Dimiliki oleh Institusi | 67.11% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Bvf Inc/Il | 31 Dec 2025 | 1,559,595 |
| Two Seas Capital Lp | 31 Dec 2025 | 745,185 |
| Prosight Management, Lp | 31 Dec 2025 | 554,633 |
| Sofinnova Investments, Inc. | 31 Dec 2025 | 438,630 |
| Emerald Advisers, Llc | 31 Dec 2025 | 384,342 |
| 22Nw, Lp | 31 Dec 2025 | 331,115 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 165.00 (HC Wainwright & Co., 90.24%) | Beli |
| Median | 151.00 (74.09%) | |
| Rendah | 150.00 (B. Riley Securities, 72.94%) | Beli |
| Purata | 155.33 (79.09%) | |
| Jumlah | 3 Beli | |
| Harga Purata @ Panggilan | 61.87 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| B. Riley Securities | 23 Feb 2026 | 150.00 (72.94%) | Beli | 73.62 |
| BTIG | 10 Feb 2026 | 151.00 (74.09%) | Beli | 56.00 |
| 29 Jan 2026 | 118.00 (36.05%) | Beli | 35.23 | |
| HC Wainwright & Co. | 10 Feb 2026 | 165.00 (90.23%) | Beli | 56.00 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 30 Jan 2026 | Pengumuman | Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |